Hana Biosciences, SupplyScape, Galenea, and Mpex Pharmaceuticals have all had people on the move in the world of pharmaceutical manufacturing.
Hana Biosciences announced the promotion of Dr Hana Moran to vice president of regulatory affairs and quality assurance.
Moran joined Hana Biosciences in December last year as a senior director of regulatory affairs and Quality assurance after more than 24 years of pharmaceutical industry experience in research, regulatory affairs and quality assurance.
"Dr Moran's outstanding experience and achievements in the biopharmaceutical industry generally, and regulatory and clinical affairs specifically, have significantly contributed to moving our company forward," Hana Biosciences president and chief executive Mark Ahn said.
"We look forward to her continued guidance and leadership as we advance multiple oncology and supportive care therapeutics through clinical development and commercialization." Meanwhile, Cardinal Health veteran Dirk Rodgers has been appointed director of industry standards at SupplyScape, a provider of supply chain software for the pharmaceutical supply chain.
Rodgers brings more than 20 years of supply chain and pharmaceutical operations technology experience to SupplyScape, including his time at Cardinal Health, when he was a senior systems architect for supply chain solutions. He was also involved in Cardinal Health's radio frequency identification (RFID) pilots.
His appointment should cement SupplyScape's leadership in areas of technology, such as RFID, according to the company.
"Dirk's industry expertise and EPCglobal stewardship experience, combined with SupplyScape's adoption leadership, will translate into more standards that address industry needs," SupplyScape senior vice president of products and Software-as-a-Service Peter Spellman said.
"Dirk's continued presence in these evolving standards efforts will help ensure their viability for the industry."
Other people on the move include Dr Mark Benjamin, who has been appointed president and chief executive of Galenea, a biopharmaceutical company focussed on developing drugs to treat schizophrenia and other central nervous system diseases.
Benjamin brings 16 years of experience in the pharmaceutical and biotech industries, including 13 years in business development. He was previously chief business officer of Nura, a neuroscience drug discovery company.
"Mark's significant experience in both drug discovery and development make him an ideal candidate to lead this company in the next phase of our growth," Galenea vice president of central nervous system research Dr. David Gerber said.
"His strong scientific background and broad business experience will be essential as we advance our collaboration with Otsuka Pharmaceuticals and initiate new corporate alliances."
Galenea has secured $50m (€37m) in financing from Japan-based Otsuka Pharmaceuticals for discovering schizophrenia treatments.
A chief executive role at Mpex Pharmaceuticals has been filed by Daniel Burgess, who joins the company from Hollia-Eden where he was the chief operating officer and chief financial officer since 1999.
Burgess said he was "thrilled" to be joining the biopharmaceutical company which focuses on the discovery and development of antibacterials.
"The need for new antibiotic approaches is great, and the highly experienced scientific staff at Mpex has positioned the company well to be able to offer innovative solutions to meet this need. I look forward to working with this talented group to bring important new options to patients."